Impax Laboratories Inc. (IPXL) announced after the bell Monday that it has received approval from the FDA for a generic version of Renvela tablets, 800 mg. The stock is now up 1.05 on 34K shares.
Impax Laboratories gapped down slightly Monday and fell during the first hour of trade, before settling into a range. Shares finished with a loss of 0.90 at $20.35.
For comments and feedback contact: editorial@rttnews.com
Business News